PMID- 28272808
OWN - NLM
STAT- MEDLINE
DCOM- 20180404
LR  - 20220330
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 40
IP  - 7
DP  - 2017 Jul
TI  - Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure 
      System.
PG  - 430-436
LID - 10.1002/clc.22696 [doi]
AB  - Heart failure (HF) is a leading cause of cardiovascular mortality in the United 
      States and presents a substantial economic burden. A recently approved 
      implantable wireless pulmonary artery pressure remote monitor, the CardioMEMS HF 
      System, has been shown to be effective in reducing hospitalizations among New 
      York Heart Association (NYHA) class III HF patients. The objective of this study 
      was to estimate the cost-effectiveness of this remote monitoring technology 
      compared to standard of care treatment for HF. A Markov cohort model relying on 
      the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve 
      Outcomes in NYHA Class III Heart Failure Patients) clinical trial for mortality 
      and hospitalization data, published sources for cost data, and a mix of CHAMPION 
      data and published sources for utility data, was developed. The model compares 
      outcomes over 5 years for implanted vs standard of care patients, allowing 
      patients to accrue costs and utilities while they remain alive. Sensitivity 
      analyses explored uncertainty in input parameters. The CardioMEMS HF System was 
      found to be cost-effective, with an incremental cost-effectiveness ratio of 
      $44,832 per quality-adjusted life year (QALY). Sensitivity analysis found the 
      model was sensitive to the device cost and to whether mortality benefits were 
      sustained, although there were no scenarios in which the cost/QALY exceeded 
      $100,000. Compared with standard of care, the CardioMEMS HF System was 
      cost-effective when leveraging trial data to populate the model.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - Schmier, Jordana K
AU  - Schmier JK
AD  - Department of Health Sciences Exponent, Alexandria, Virginia.
FAU - Ong, Kevin L
AU  - Ong KL
AD  - Department of Biomedical Engineering, Exponent, Philadelphia, Pennsylvania.
FAU - Fonarow, Gregg C
AU  - Fonarow GC
AUID- ORCID: 0000-0002-3192-8093
AD  - Division of Cardiology, Department of Medicine, Ronald Reagan UCLA Medical 
      Center, Los Angeles, California.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20170308
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
SB  - IM
MH  - Aged
MH  - Cost-Benefit Analysis
MH  - Follow-Up Studies
MH  - *Health Care Costs
MH  - Heart Failure/*diagnosis/economics/therapy
MH  - Hospitalization/economics
MH  - Humans
MH  - Male
MH  - Monitoring, Physiologic/*economics/methods
MH  - Retrospective Studies
MH  - Telemetry/*economics/instrumentation/standards
MH  - Time Factors
MH  - United States
PMC - PMC6490396
OTO - NOTNLM
OT  - cost effectiveness
OT  - economic analysis
OT  - heart failure
OT  - monitoring
OT  - quality
COIS- Authors Jordana K. Schmier and Kevin L. Ong are employed by Exponent. Exponent 
      received a grant from St. Jude Medical to evaluate the cost-effectiveness of its 
      implantable remote monitoring system. Dr. Fonarow has served as a consultant to 
      St. Jude Medical. St. Jude Medical has reviewed the manuscript prior to 
      submission, but did not provide substantial scientific input.
EDAT- 2017/03/09 06:00
MHDA- 2018/04/05 06:00
PMCR- 2017/03/08
CRDT- 2017/03/09 06:00
PHST- 2016/10/13 00:00 [received]
PHST- 2017/01/11 00:00 [revised]
PHST- 2017/01/31 00:00 [accepted]
PHST- 2017/03/09 06:00 [pubmed]
PHST- 2018/04/05 06:00 [medline]
PHST- 2017/03/09 06:00 [entrez]
PHST- 2017/03/08 00:00 [pmc-release]
AID - CLC22696 [pii]
AID - 10.1002/clc.22696 [doi]
PST - ppublish
SO  - Clin Cardiol. 2017 Jul;40(7):430-436. doi: 10.1002/clc.22696. Epub 2017 Mar 8.